Document is current
Any future updates will be listed below
-
Authors
Nakai, Shigeto
Makino, Tomoki https://orcid.org/0000-0001-7918-4217
Momose, Kota
Yamashita, Kotaro
Tanaka, Koji
Miyata, Hiroshi
Yamamoto, Sachiko
Motoori, Masaaki
Kimura, Yutaka
Kawabata, Ryohei
Hirao, Motohiro
Matsuyama, Jin
Akamaru, Yusuke
Morihara, Hitomi
Ueyama, Azumi
Kurokawa, Yukinori
Morii, Eiichi
Wada, Hisashi
Eguchi, Hidetoshi
Doki, Yuichiro
-
Funding
Funding for this research was provided by:
Takeda Science Foundation
a Grant-in-Aid for Scientific Research (21K08776, 24K11865)
Princess Takamatsu Cancer Research Fund
the Japan Research Foundation for Clinical Pharmacology
Uehara Memorial Foundation
The University of Osaka
- License Information
-
More Information
Article History
Received: 10 January 2025
Accepted: 11 March 2025
First Online: 24 April 2025
Declarations
:
: All studies were performed in accordance with the ethical guidelines of the Declaration of Helsinki and Japanese Ethical Guidelines for Human Genome/Gene Analysis Research. The use of resected samples and clinicopathological data was approved by the Human Ethics Review Committee of the Graduate School of Medicine, Osaka University (no. 19146-5). This study is registered with UMIN Clinical Trials Registry, number UMIN000040462. Included patients gave written informed consent before enrollment, which was not required for patients who had died or been lost to follow-up.
